Evidence map›Paper›PMID 24444522›Full record

ReviewMedicina clinica2013

[Sodium-glucose co-transporter-2 inhibitors: from the bark of apple trees and familial renal glycosuria to the treatment of type 2 diabetes mellitus].

Dídac Mauricio

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Medicina clinica, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03132181 (Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03132181 phase2completedstarted 2017, after this paper: background citation

Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes

Ran2017Enrolled40Registered outcomes14Posted comparisons0ConditionsDiabetes Mellitus Type 2 (T2DM)Armsempagliflozin, Placebo
PMID 24939043PMID 27299675PMID 23735727PMID 24026259PMID 24475922PMID 26343814PMID 26981940other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Dídac MauricioServicio de Endocrinología y Nutrición, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España. Electronic address: didacmauricio@gmail.com.
Hospital Universitari Germans Trias i Pujol · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic armamentarium for the treatment of hyperglycemia in type 2 diabetes mellitus is still inadequate. We are currently witnessing the introduction of a new mode of hypoglycemic treatment through induction of glycosuria to decrease the availability of the metabolic substrate, i.e. glucose. Clinical trials have shown that sodium-glucose co-transporter-2 (SGLT2) inhibitors are as efficacious as other oral hypoglycemic drugs. This article discusses the basic features of this new treatment concept and the efficacy and safety of this new drug group.

Indexed as

AdsorptionAnimalsBenzhydryl CompoundsBiological Transport, ActiveCanagliflozinClinical Trials, Phase III as TopicDiabetes Mellitus, Type 2Drugs, InvestigationalGlucoseGlucosidesGlycosidesGlycosuriaGlycosuria, RenalHumansHypoglycemic AgentsKidney Tubules, Proximal(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triolBenzhydryl CompoundsCanagliflozindapagliflozinDrugs, InvestigationalempagliflozinGlucoseGlucosidesGlycosidesHypoglycemic AgentsipragliflozinPhlorhizinSLC5A2 protein, humanSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsThiophenesDiabetes mellitus tipo 2EfficacyEficaciaGlucosuriaGlycosuriaInhibidores del cotransportador sodio/glucosa tipo 2SafetySeguridadType 2 diabetes mellitusType 2 sodium/glucose co-transporter inhibitors

Identifiers

PMID24444522
OpenAlexW2005038289

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.